Saturday, 31 October 2026European Markets

KORIAN Stock Bearish By 19% At Session Start On Wednesday

Loading stream...

(vianews) - shares of korian (cac 40: kori.pa) slid by a staggering 19.39% to €7.69 at 10:54 est on wednesday, following the last session's upward trend. cac 40 is sliding 0.89% to €7,243.92, after three consecutive sessions in a row of losses. this seems, as yet, a somewhat down trend exchanging session today.

about korian

korian provides a range of medical and non-medical care and support services for the elderly and people with short or longer-term health issues. the company operates long-term care nursing homes, specialized clinics, and assisted living and shared housing facilities for seniors, as well as offers home care, support, and hospitalization services. as of december 31, 2021, it operated with 91,808 beds. the company operates approximately 850 care facilities and networks in france, germany, italy, spain, the netherlands, and belgium. the company was formerly known as korian-medica s.a. and changed its name to korian in july 2015. korian was founded in 2001 and is based in paris, france.

earnings per share

as for profitability, korian has a trailing twelve months eps of €0.3.

pe ratio

korian has a trailing twelve months price to earnings ratio of 25.55. meaning, the purchaser of the share is investing €25.55 for every euro of annual earnings.

volatility

korian's last week, last month's, and last quarter's current intraday variation average was a positive 1.01%, a negative 0.13%, and a positive 1.80%.

korian's highest amplitude of average volatility was 2.11% (last week), 1.80% (last month), and 1.80% (last quarter).

volume

today's last reported volume for korian is 2316093 which is 394.72% above its average volume of 468157.

more news about korian (kori.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com